The US Food and Drug Administration approved nirogacestat (Ogsiveo, SpringWorks Therapeutics, Inc) to treat progressive, unresectable, recurrent, or refractory desmoid tumors in adults. Nirogacestat, an oral […]
The US Food and Drug Administration (FDA) has approved enzalutamide (Xtandi, Astellas and Pfizer) for men with nonmetastatic castration-sensitive prostate cancer who experience biochemical recurrence and […]
The US Food and Drug Administration (FDA) has approved the immune checkpoint inhibitor pembrolizumab (Keytruda, Merck) with fluoropyrimidine- and platinum-containing chemotherapy for first-line treatment of adult […]
The US Food and Drug Administration (FDA) has approved capivasertib (Truqap, AstraZeneca Pharmaceuticals) with fulvestrant for certain previously treated adults with hormone receptor (HR)–positive, human epidermal […]
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.